Patents by Inventor Pavel Lazarev
Pavel Lazarev has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 12094610Abstract: An in vitro human-tissue analysis and communication system produces a quantitative diagnostic indicator for in vitro human-tissue analyzed by the system. The system includes a human-tissue-analyzer subsystem with at least one human-tissue analyzer that analyzes in vitro samples of human tissue and produces a quantitative-diagnostic indicator of each sample. The system also includes a two-way communication subsystem that allows the human-tissue-analyzer subsystem to send and receive information relevant to the quantitative-diagnostic indicators. The human-tissue-analyzer subsystem includes at least one tissue diffractometer operatively coupled to a computer database over a network, and configured for acquisition of the in vitro samples, and transfer of the corresponding human-tissue data to the computer database over the network.Type: GrantFiled: September 26, 2021Date of Patent: September 17, 2024Assignee: Bragg Analytics, Inc.Inventors: Alexander Lazarev, Pavel Lazarev, Delvin Tai Wai Yuk
-
Patent number: 12094609Abstract: An animal-tissue analysis and communication system produces a quantitative-diagnostic indicator for animal-tissue analyzed by the system. The system includes an animal-tissue-analyzer subsystem with at least one animal-tissue analyzer constructed to analyze animal tissue and to produce an quantitative-diagnostic indicator. The system also includes a two-way communication subsystem constructed to allow the animal-tissue-analyzer subsystem to send and receive information relevant to the quantitative-diagnostic indicator. The animal-tissue-analyzer subsystem includes at least one tissue diffractometer operatively coupled to a computer database over a network, and is configured for acquisition and transfer of animal-tissue data, and transfer to the computer database over the network.Type: GrantFiled: September 26, 2021Date of Patent: September 17, 2024Assignee: Arion Diagnostics, Inc.Inventors: Alexander Lazarev, Pavel Lazarev, Delvin Tai Wai Yuk
-
Publication number: 20240161893Abstract: The present disclosure relates to determining a therapy efficacy. A method for determining an efficacy of a therapy for a disease in a human patient can include measuring a molecular structure of a biological tissue of a patient at a first time and at a second time using a non-invasive biological tissue characterization technique. The method can further include observing a change of the molecular structure of the biological tissue between the first time and the second time, and determining the efficacy of the therapy based on the observed change in the molecular structure of the biological tissue. Before the first time, or between the first time and the second time, the patient received the therapy.Type: ApplicationFiled: November 16, 2022Publication date: May 16, 2024Applicant: EosDx Inc.Inventors: Alexander P. Lazarev, Delvin Tai Wai YUK, Pavel Lazarev
-
Publication number: 20240016462Abstract: In some embodiments, an X-ray system comprises a work-station and a mammography apparatus. The mammography apparatus can comprise: a breast positioning area; an absorption contrast imaging apparatus; and a diffractometer for analyzing structure of tissue within a breast. The absorption contrast imaging apparatus and the diffractometer can be configured to move in order to interchangeably align with the breast positioning area. The work-station can be configured to control the mammography apparatus, and to process data received from the mammography apparatus.Type: ApplicationFiled: July 13, 2023Publication date: January 18, 2024Applicant: EosDx Inc.Inventors: Alexander P. LAZAREV, Pavel LAZAREV
-
Publication number: 20240000412Abstract: In some embodiments an X-ray system comprises a work-station and a mammography apparatus. The mammography apparatus can comprise: a breast positioning area; a diffraction enhanced X-ray imaging apparatus; and a diffractometer for analyzing structure of tissue within a breast. The diffraction enhanced X-ray imaging apparatus and the diffractometer can be configured to move in order to interchangeably align with the breast positioning area. The work-station can be configured to control, and to process data received from, the mammography apparatus.Type: ApplicationFiled: July 13, 2023Publication date: January 4, 2024Applicant: EosDx Inc.Inventors: Alexander P. LAZAREV, Pavel LAZAREV
-
Patent number: 11751828Abstract: An in vivo human-tissue analysis and communication system produces a quantitative diagnostic indicator for human-tissue analyzed by the system. The system includes a human-tissue-analyzer subsystem with at least one human-tissue analyzer constructed to analyze human tissue and to produce a quantitative-diagnostic indicator. There is also a two-way communication subsystem constructed to allow the human-tissue-analyzer subsystem to send and receive information relevant to the quantitative-diagnostic indicator. The human-tissue-analyzer subsystem includes at least one tissue diffractometer operatively coupled to a computer database over a network, and configured for acquisition of human-tissue data and transfer to the computer database over the network.Type: GrantFiled: September 26, 2021Date of Patent: September 12, 2023Assignee: EosDx Inc.Inventors: Alexander Lazarev, Pavel Lazarev, Delvin Tai Wai Yuk
-
Publication number: 20230270396Abstract: The present disclosure relates to determining an efficacy of a therapeutic agent. A method for determining an efficacy of a therapeutic agent for a target disease can include measuring a molecular structure of a biological tissue of an animal at a first time and at a second time using a non-invasive biological tissue characterization technique. The method can further include observing a change of the molecular structure of the biological tissue between the first time and the second time, and determining the efficacy of the therapeutic agent based on the observed change in the molecular structure of the biological tissue. Before the first time, or between the first time and the second time, the animal received the therapeutic agent.Type: ApplicationFiled: April 10, 2023Publication date: August 31, 2023Applicant: Arion Diagnostics, Inc.Inventors: Alexander P. LAZAREV, Delvin Tai Wai YUK, Pavel LAZAREV
-
Publication number: 20230240635Abstract: The present disclosure relates to determining a therapy efficacy. A method for determining an efficacy of a therapy for a disease in an animal patient can include measuring a molecular structure of a biological tissue of an animal patient at a first time and at a second time using a non-invasive biological tissue characterization technique. The method can further include observing a change of the molecular structure of the biological tissue between the first time and the second time, and determining the efficacy of the therapy based on the observed change in the molecular structure of the biological tissue. Before the first time, or between the first time and the second time, the animal patient received the therapy.Type: ApplicationFiled: April 10, 2023Publication date: August 3, 2023Applicant: Arion Diagnostics, Inc.Inventors: Alexander P. LAZAREV, Delvin Tai Wai YUK, Pavel LAZAREV
-
Publication number: 20230240636Abstract: The present disclosure relates to determining a biological tissue structural marker for diagnosis of a disease using a biological tissue characterization technique. A method for determining a structural marker for a diagnosis of a disease can include measuring a first molecular structure of a biological tissue of a first population of animals, after a carcinogenic or pathogenic substance was introduced into the first population. A second molecular structure of the biological tissue of a second population of animals can be measured, wherein the second population did not receive the carcinogenic or pathogenic substance. A first and a second structural marker of the molecular structures of the biological tissue of the first and second populations, respectively, can be identified and compared to determine that the first structural marker is indicative that the biological tissue of the first population of animals was affected by the disease.Type: ApplicationFiled: April 10, 2023Publication date: August 3, 2023Applicant: Arion Diagnostics, Inc.Inventors: Alexander P. LAZAREV, Delvin Tai Wai YUK, Pavel LAZAREV
-
Publication number: 20230207074Abstract: Provided herein are diffractometer-based global diagnostic systems and uses thereof. The systems may comprise one or more diffraction apparatus operatively coupled to a computer database over a network. The one or more diffraction apparatus may be configured for transfer of data such as pathology lab image data, diffraction pattern data, subject data, or any combination thereof to the computer database over the network. The systems may further comprise one or more computer processors operatively coupled to the one or more diffraction apparatus, which computer processors may be configured to receive the data from the diffraction apparatus, transmit the data to the computer database, and process the data using a data analytics algorithm which may provide a computer-aided diagnostic indicator for the individual subject.Type: ApplicationFiled: June 14, 2021Publication date: June 29, 2023Applicant: Bragg Analytics, Inc.Inventors: Pavel LAZAREV, Alexander LAZAREV
-
Patent number: 11607188Abstract: Provided herein are diffractometer-based global in situ diagnostic systems and uses thereof. The systems may comprise one or more tissue diffractometers that are configured for acquiring in situ diffraction data for a subject, e.g., a patient, and that are operatively coupled to a computer database over a network. The one or more tissue diffractometers may be configured for transfer of data such as image data, diffraction pattern data, subject data, or any combination thereof to the computer database over the network. The systems may further comprise one or more computer processors operatively coupled to the tissue diffractometers, which computer processors may be configured to receive the data from the tissue diffractometers, transmit the data to the computer database, and process the data using a data analytics algorithm which may provide a computer-aided diagnostic indicator for the individual subject.Type: GrantFiled: June 14, 2021Date of Patent: March 21, 2023Assignee: EosDx Inc.Inventors: Pavel Lazarev, Alexander Lazarev
-
Publication number: 20220415505Abstract: Provided herein are diffractometer-based global in situ diagnostic systems and uses thereof. The systems may comprise one or more tissue diffractometers that are configured for acquiring in situ diffraction data for a subject, e.g., a patient, and that are operatively coupled to a computer database over a network. The one or more tissue diffractometers may be configured for transfer of data such as image data, diffraction pattern data, subject data, or any combination thereof to the computer database over the network. The systems may further comprise one or more computer processors operatively coupled to the tissue diffractometers, which computer processors may be configured to receive the data from the tissue diffractometers, transmit the data to the computer database, and process the data using a data analytics algorithm which may provide a computer-aided diagnostic indicator for the individual subject.Type: ApplicationFiled: June 14, 2021Publication date: December 29, 2022Applicant: NISTA Diagnostics Inc.Inventors: Pavel LAZAREV, Alexander LAZAREV
-
Publication number: 20220008027Abstract: An in vivo human-tissue analysis and communication system produces a quantitative diagnostic indicator for human-tissue analyzed by the system. The system includes a human-tissue-analyzer subsystem with at least one human-tissue analyzer constructed to analyze human tissue and to produce a quantitative-diagnostic indicator. There is also a two-way communication subsystem constructed to allow the human-tissue-analyzer subsystem to send and receive information relevant to the quantitative-diagnostic indicator. The human-tissue-analyzer subsystem includes at least one tissue diffractometer operatively coupled to a computer database over a network, and configured for acquisition of human-tissue data and transfer to the computer database over the network.Type: ApplicationFiled: September 26, 2021Publication date: January 13, 2022Applicant: NISTA Diagnostics Inc.Inventors: Alexander LAZAREV, Pavel LAZAREV, Delvin Tai Wai YUK
-
Publication number: 20220013233Abstract: An in vitro human-tissue analysis and communication system produces a quantitative diagnostic indicator for in vitro human-tissue analyzed by the system. The system includes a human-tissue-analyzer subsystem with at least one human-tissue analyzer that analyzes in vitro samples of human tissue and produces a quantitative-diagnostic indicator of each sample. The system also includes a two-way communication subsystem that allows the human-tissue-analyzer subsystem to send and receive information relevant to the quantitative-diagnostic indicators. The human-tissue-analyzer subsystem includes at least one tissue diffractometer operatively coupled to a computer database over a network, and configured for acquisition of the in vitro samples, and transfer of the corresponding human-tissue data to the computer database over the network.Type: ApplicationFiled: September 26, 2021Publication date: January 13, 2022Applicant: Bragg Analytics, Inc.Inventors: Alexander LAZAREV, Pavel LAZAREV, Delvin Tai Wai YUK
-
Publication number: 20220013227Abstract: An animal-tissue analysis and communication system produces a quantitative-diagnostic indicator for animal-tissue analyzed by the system. The system includes an animal-tissue-analyzer subsystem with at least one animal-tissue analyzer constructed to analyze animal tissue and to produce an quantitative-diagnostic indicator. The system also includes a two-way communication subsystem constructed to allow the animal-tissue-analyzer subsystem to send and receive information relevant to the quantitative-diagnostic indicator. The animal-tissue-analyzer subsystem includes at least one tissue diffractometer operatively coupled to a computer database over a network, and is configured for acquisition and transfer of animal-tissue data, and transfer to the computer database over the network.Type: ApplicationFiled: September 26, 2021Publication date: January 13, 2022Applicant: Arion Diagnostics, Inc.Inventors: Alexander LAZAREV, Pavel LAZAREV, Delvin Tai Wai YUK
-
Publication number: 20200255453Abstract: The present disclosure provides an energy storage molecular material, crystal dielectric layer and capacitor which may solve a problem of the further increase of volumetric and mass density of reserved energy associated with some energy storage devices, and at the same time reduce cost of materials.Type: ApplicationFiled: February 14, 2020Publication date: August 13, 2020Inventor: Pavel Lazarev
-
Patent number: 10597407Abstract: The present disclosure provides an energy storage molecular material, crystal dielectric layer and capacitor which may solve a problem of the further increase of volumetric and mass density of reserved energy associated with some energy storage devices, and at the same time reduce cost of materials.Type: GrantFiled: April 3, 2018Date of Patent: March 24, 2020Assignee: CAPACITOR SCIENCES INCORPORATEDInventor: Pavel Lazarev
-
Publication number: 20180222924Abstract: The present disclosure provides an energy storage molecular material, crystal dielectric layer and capacitor which may solve a problem of the further increase of volumetric and mass density of reserved energy associated with some energy storage devices, and at the same time reduce cost of materials.Type: ApplicationFiled: April 3, 2018Publication date: August 9, 2018Inventor: Pavel Lazarev
-
Patent number: 9515207Abstract: The present invention relates generally to the field of photovoltaic devices and particularly to the organic photovoltaic layer. More specifically, the organic photovoltaic layer comprises at least one organic compound of the general structural formula where Het1 and Het2 are predominantly planar polycyclic molecular systems; A is a bridging group providing a lateral bond of the molecular systems; and X is a counterion from a list comprising H+, Li+, Na+, K+, NH4+, Ba++, Zn++, Sr++, Ca++, Mg++, and any combination thereof. The photovoltaic layer is formed of column-like or planar supramolecules, it has absorption of electromagnetic radiation in at least one predetermined spectral subrange within a wavelength range from 400 to 3000 nm, and the molecular system Het1, the bridging group A, and the molecular system Het2 form a donor-bridge-acceptor system providing dissociation of excited electron-hole pairs.Type: GrantFiled: September 3, 2013Date of Patent: December 6, 2016Assignee: Cryscade Solar LimitedInventor: Pavel Lazarev
-
Publication number: 20160196929Abstract: An electrochemical energy storage device includes a first polymer electrode and a second polymer electrode spaced apart from the first polymer electrode such that a space is reserved between the first and second polymer electrodes. The space reserved between the first and second polymer electrodes contains an electrolyte that comprises a quinone compound. The first and second polymer electrodes each consist essentially of acid-dopable polymers.Type: ApplicationFiled: August 15, 2014Publication date: July 7, 2016Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: David VONLANTHEN, Fred WUDL, Alan J. HEEGER, Pavel LAZAREV